

Date: 28<sup>th</sup> May, 2022

BSE Ltd.  
Corporate Service Department  
1<sup>st</sup> Floor, P.J. Towers,  
Dalal Street,  
Mumbai 400 001

The National Stock Exchange of India Ltd.  
Exchange Plaza, 3<sup>rd</sup> Floor,  
Plot No. C/1, 'G' Block,  
Bandra Kurla Complex, Bandra (E),  
Mumbai 400 051

Scrip ID: KRSNAA  
Scrip Code: 543328

Symbol: KRSNAA  
Series: EQ

Dear Sir/Madam,

Subject: Outcome of Board Meeting

This is to inform you that the Board of Directors of the Company at its meeting held today, which commenced at 3:00 p.m. and concluded at 7:30 p.m., inter-alia, unanimously approved/consented/took on record the following:

1. Financial Results:

- Audited (Standalone and Consolidated) Financial Results of the Company for the quarter and year ended 31<sup>st</sup> March, 2022.
- Audited (Standalone and Consolidated) Financial Results of the Company for the year ended 31<sup>st</sup> March, 2022.

The aforesaid Auditor's Report for the period ended 31<sup>st</sup> March, 2022 is with unmodified opinion.

2. Final Dividend:

- Recommendation of final dividend at INR 2.50 (50%) per equity share of INR 5.00 each, for FY 2021-22, subject to approval by Members at the ensuing Annual General Meeting ("AGM").
- The dividend, if approved, shall be paid/dispatched to the shareholders within 30 days of its approval by the shareholders, at the ensuing Annual General Meeting.

3. Change in Board of Directors:

a. Appointment of Director

Appointment of Mr. Adesh Kumar Gupta (DIN: 00020403) as Independent Director, on the Board of the Company, for a term of 5 years effective from 28<sup>th</sup> May, 2022, subject to Member's and other applicable approval(s), Further details pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, are enclosed as Annexure A.

b. Resignation of Director

Mr. Prakash Iyer (DIN: 00529591), has tendered his resignation from the post of Independent Director of the Company w.e.f. close of business hours on 28<sup>th</sup> May, 2022. The same has been taken on record by the Board of Directors in the Meeting held today. Further details pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, are enclosed as Annexure B.

It is requested to take this intimation on your records.

Thanking you,  
Yours sincerely,

For Krsnaa Diagnostics Limited



Nikhil Deshpande  
Company Secretary




**Encl.:** As mentioned above.

[Regulation 30 read with Para A of Part A of Schedule III to SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015]

Appointment of Mr. Adesh Kumar Gupta as an Independent Director of the Company


Brief Profile	Name of Director	Adesh Kumar Gupta
	Date of Birth	11/09/1956
	Address	701, Tagore Avenue, Tagore Road, Santacruz West, Mumbai, Maharashtra, India 400054
	E-mail	<a href="mailto:adeshkgupta@adeshg.com">adeshkgupta@adeshg.com</a>
	Professional and Educational Qualifications	Chartered Accountant, Company Secretary and AMP (Harvard)
	Occupation	Professional
	List of Companies/Firms of outside Directorships	<ol style="list-style-type: none"> <li>1. Grasim Industries Limited</li> <li>2. India Pesticides Limited</li> <li>3. Vinati Organics Limited</li> <li>4. Care Ratings Limited</li> <li>5. Zee Entertainment Enterprise Limited</li> <li>6. Krazybee Services Private Limited</li> </ol>
Experience	<p>Mr. Adesh Gupta is a Qualified Chartered Accountant, Company Secretary and AMP from Harvard is a professional with rich experience of over more than 40 years in Corporate Strategy, M&amp;A, Business restructuring, Fund raising, Taxation etc.</p> <p>During his distinguished career of over 3 decades in Aditya Birla Group, Mr. Gupta held various senior positions including board positions in various companies of the group including Indian Rayon, Birla Global Finance, Aditya Birla Nuvo Limited and Grasim Industries Limited. Currently, he is working as insolvency professional.</p> <p>He was awarded with Best CFO award by ICAI, IMA and Business Today. He had also represented FICCI as a Member of NACAS which was instrumental in setting up Accounting Standards in India.</p>	
Reason for change viz. appointment	Pursuant to recommendation of the Nomination and Remuneration Committee vide its meeting held on 28 <sup>th</sup> May, 2022, the Board of Directors approved the appointment of Mr. Adesh Kumar Gupta (DIN:00020403) as Independent Director of the Company.	
Date of Appointment and term of appointment	<p>Date: 28<sup>th</sup> May, 2022.</p> <p>Terms: 5 years from 28<sup>th</sup> May, 2022, subject to Member's and other requisite approval(s).</p>	

Disclosure of relationships between Directors	Mr. Adesh Kumar Gupta (DIN:00020403 )is not related to any other Director(s) presently on the Board.
Affirmation	Based on the information provided to the Company, Mr. Adesh Kumar Gupta is not debarred from holding the office of a Director by virtue of any SEBI order or any such authority.



[Regulation 30 read with Para A of Part A of Schedule III to SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015]

Sr. No.	Requirement	Disclosure
1	Reason for change viz., appointment; resignation, removal, death or otherwise.	Resignation due to personal reasons.
2	Date of <del>appointment</del> / cessation (as applicable) and term of appointment	Effective from close of business hours on 28 <sup>th</sup> May, 2022.
3	Brief Profile (in case of appointment)	NA
4	Disclosure of relationships between directors (in case of appointment of a director)	



**Independent Auditor's Report on Quarterly Consolidated Financial Results and Year to Date Consolidated Financial Results pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015**

**To the Board of Directors of Krsnaa Diagnostics Limited**

**Report on the Audit of Consolidated Financial Results**

**Opinion**

We have audited the accompanying consolidated annual financial results of Krsnaa Diagnostics Limited (hereinafter referred to as the 'Holding Company') and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), for the quarter and year ended March 31, 2022, ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate audited financial statements of the subsidiaries, the aforesaid Statement:

(i) include the annual financial results of the following entities

Sr. No	Name of the Entity	Relationship with the Holding Company
1.	KDPL Diagnostics (Amritsar) Private Limited	Wholly Owned Subsidiary
2.	KDPL Diagnostics (Bathinda) Private Limited	Wholly Owned Subsidiary
3.	KDPL Diagnostics (Jalandhar) Private Limited	Wholly Owned Subsidiary
4.	KDPL Diagnostics (Ludhiana) Private Limited	Wholly Owned Subsidiary
5.	KDPL Diagnostics (Patiala) Private Limited	Wholly Owned Subsidiary
6.	KDPL Diagnostics (SAS Nagar) Private Limited	Wholly Owned Subsidiary
7.	Krsnaa Diagnostics (Mohali) Private Limited	Wholly Owned Subsidiary

(ii) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

(iii) give a true and fair view in conformity with the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India, of net profit and other comprehensive income and other financial information of the Group for the year ended March 31, 2022.



## **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

## **Board of Directors' Responsibilities for the Consolidated Financial Results**

These Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, have been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of this Statement that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the companies included in the Group entities are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.



The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

**Auditor’s Responsibilities for the Audit of the Consolidated Financial Results**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor’s report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor’s report. However, future events or conditions may cause the Group to cease to continue as a going concern.





- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities within the Group to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the Statement of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent possible.

#### **Other Matters**

1. The Statement includes the audited Financial Results of seven (7) subsidiaries, whose Financial Statements reflect Group's share of total assets of Rs. 10.62 Million as at March 31, 2022, Group's share of total revenue of Rs. 15.97 Million and Rs. 21.29 Million and Group's share of total net loss after tax of Rs. 13.93 and Rs. 23.14, Group's share of total comprehensive income (i.e. loss) of Rs. (14.21) Millions and Rs. (23.41) Millions for the quarter ended March 31, 2022 and for the year ended March 31, 2022 respectively and cash inflow of Rs. 1.29 Million as considered in the Statement, which have been audited by their respective independent auditors. The independent auditors' reports on financial statements of these entities have been furnished to us and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.



2. The Statement includes the results for the quarter ended March 31, 2022 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" which were subject to limited review by us.

Our opinion on the Statement is not modified in respect of the above matters.

**For M S K A & Associates**  
Chartered Accountants  
ICAI Firm Registration No.105047W

**NITIN**  
**MANOHA**  
**R JUMANI**

Digitally signed  
by NITIN  
MANOHAR  
JUMANI  
Date: 2022.05.28  
16:01:49 +05'30'



**Nitin Manohar Jumani**  
Partner  
Membership No. 111700  
UDIN: 22111700AJUPCZ3563

Place: Pune  
Date: May 28, 2022

Statement of Consolidated Financial Results for the quarter and year ended March 31, 2022

(INR Million, except earnings per share)

Sr. No.	Particulars	Quarter ended		Year ended
		March 31, 2022	December 31, 2021	March 31, 2022
		(Audited)	(Un-audited)	(Audited)
<b>1</b>	<b>Income</b>			
	Revenue from operations	1,082.47	1,064.68	4,554.50
	Other income	41.04	43.39	149.11
	<b>Total Income</b>	<b>1,123.51</b>	<b>1,108.07</b>	<b>4,703.61</b>
<b>2</b>	<b>Expenses</b>			
	Cost of material consumed	127.03	117.46	602.96
	Employee benefits expense	152.62	142.59	547.47
	Finance costs	17.96	23.59	184.90
	Depreciation and amortization expense	104.45	106.34	413.87
	Fees to hospitals and others	248.30	274.38	1,079.92
	Other expenses	274.26	230.17	1,009.39
	<b>Total Expenses</b>	<b>924.62</b>	<b>894.53</b>	<b>3,838.51</b>
<b>3</b>	<b>Profit before tax (1) - (2)</b>	<b>198.89</b>	<b>213.54</b>	<b>865.10</b>
<b>4</b>	<b>Tax expenses</b>			
	Income tax charge	51.88	44.61	175.26
	Deferred tax charge/(credit)	(32.35)	5.60	5.94
	<b>Total tax expenses</b>	<b>19.53</b>	<b>50.21</b>	<b>181.20</b>
<b>5</b>	<b>Profit for the period/year (3) - (4)</b>	<b>179.36</b>	<b>163.33</b>	<b>683.90</b>
<b>6</b>	<b>Other comprehensive income</b>			
	Items that will not be reclassified subsequently to profit and loss			
	Re-measurement gains / (losses) on defined benefit plans	4.61	(0.09)	4.32
	Income tax effect	(1.16)	0.03	(1.09)
	<b>Total other comprehensive income/(loss) for the period/year</b>	<b>3.45</b>	<b>(0.06)</b>	<b>3.23</b>
<b>7</b>	<b>Total comprehensive income for the period/year, net of tax (5+6)</b>	<b>182.81</b>	<b>163.27</b>	<b>687.13</b>
	<b>Profit for the period/year</b>			
	Attributable to:			
	Equity Holders of the Holding Company	179.36	163.33	683.90
	Non Controlling Interests	-	-	-
		<b>179.36</b>	<b>163.33</b>	<b>683.90</b>
	<b>Total other comprehensive income/(loss) for the period/year</b>			
	Attributable to:			
	Equity Holders of the Holding Company	3.45	(0.06)	3.23
	Non Controlling Interests	-	-	-
		<b>3.45</b>	<b>(0.06)</b>	<b>3.23</b>
	<b>Total comprehensive income for the period/year</b>			
	Attributable to:			
	Equity Holders of the Holding Company	182.81	163.27	687.13
	Non Controlling Interests	-	-	-
		<b>182.81</b>	<b>163.27</b>	<b>687.13</b>
<b>8</b>	<b>Paid-up equity share capital (Face Value of Rs. 5/ each)</b>	156.99	156.99	156.99
	Other equity			6,687.10
	Earnings per share - After Split (Not annualised for quarters)			
	Basic (Rs.)	5.40	5.67	22.89
	Diluted (Rs.)	5.40	5.64	22.88

For and on behalf of Board of Directors  
Krsnaa Diagnostics Limited



*P. Bhatevara*  
Pallavi Bhatevara  
Managing Director  
DIN: 03600332

Krsnaa Diagnostics Limited  
(Formerly known as Krsnaa Diagnostics Private Limited)  
CIN:L74900PN2010PLC138068

Consolidated Balance Sheet as at March 31, 2022

(INR Million)

Particulars	As at March 31, 2022 (Audited)
<b>I. ASSETS</b>	
<b>Non-current assets</b>	
Property, plant and equipment	3,833.79
Capital work-in-progress	282.57
Intangible assets	23.15
<b>Financial assets</b>	
Investments	2.91
Other financial assets	1,155.15
Deferred tax asset (net)	7.88
Other non-current assets	114.61
<b>Total non-current assets</b>	<b>5,420.06</b>
<b>Current assets</b>	
Inventories	91.70
<b>Financial assets</b>	
Trade receivables	578.73
Cash and cash equivalents	884.53
Bank balances other than cash and cash equivalent	1,534.28
Other financial assets	118.56
Other current assets	133.67
<b>Total current assets</b>	<b>3,341.47</b>
<b>Total Assets</b>	<b>8,761.53</b>
<b>II. EQUITY AND LIABILITIES</b>	
<b>Equity</b>	
Equity share capital	156.99
Other equity	6,687.10
Non controlling interest	(0.00)
<b>Total equity</b>	<b>6,844.09</b>
<b>Liabilities</b>	
<b>Non-current liabilities</b>	
<b>Financial liabilities</b>	
Borrowings	196.22
Lease Liabilities	134.52
Other financial liabilities	16.38
Employee benefit obligations	3.16
Deferred Tax Liabilities	77.95
Other non-current liabilities	1.25
<b>Total non-current liabilities</b>	<b>429.48</b>
<b>Current liabilities</b>	
<b>Financial liabilities</b>	
Borrowings	60.08
Lease Liabilities	19.10
Trade payables	
i) total outstanding dues of micro enterprises and small enterprises	3.27
ii) total outstanding dues of creditors other than micro enterprise and small enterprise	769.73
Other financial liabilities	512.57
Other current liabilities	103.40
Employee benefit obligations	19.81
<b>Total Current liabilities</b>	<b>1,487.96</b>
<b>Total Liabilities</b>	<b>1,917.44</b>
<b>Total Equity and Liabilities</b>	<b>8,761.53</b>

For and on behalf of Board of Directors  
Krsnaa Diagnostics Limited



*P. Bhatevsra*

Pallavi Bhatevsra  
Managing Director  
DIN: 03600332

Place: Pune  
Date: 28.05.2022

Krsnaa Diagnostics Limited  
(Formerly known as Krsnaa Diagnostics Private Limited)  
CIN:L74900PN2010PLC138068

Statement of Consolidated Cash Flows for the year ended March 31, 2022

(INR Million.)

Particulars	Year Ended March 31, 2022 (Audited)
<b>A. Cash flow from operating activities</b>	
Profit for the period	865.10
Adjustments for:	
Depreciation and amortization expenses	413.87
Finance cost	184.90
Interest income	(122.44)
Loss on sale/disposal of assets	2.48
Provision for doubtful trade receivable balances	8.30
Effects of financial instruments measured at amortised cost	(7.49)
Employee stock option scheme compensation	12.42
<b>Operating profit before working capital changes</b>	<b>1,357.14</b>
<b>Changes in working capital</b>	
(Decrease) in trade payables	(60.04)
(Increase) in inventories	(19.61)
Decrease in trade receivables	160.33
Increase in other current liabilities	1.15
(Decrease) in other non current liabilities	(31.78)
(Decrease) in other non current financial liabilities	(58.01)
Increase in employee payables	12.81
Increase in other current financial liabilities	16.00
(Increase) in other current financial assets	(75.55)
Decrease in non current financial assets	35.45
(Increase) in other current assets	(9.35)
Decrease in other non current assets	21.99
<b>Cash generated from operations</b>	<b>1,350.53</b>
Income tax paid	(148.30)
Income tax refund received	82.01
<b>Net cash flows generated from operating activities (A)</b>	<b>1,284.24</b>
<b>B. Cash flow from Investing activities</b>	
Payment for property, plant and equipment and intangible assets	(1,322.19)
Proceeds from sale of property, plant and equipment and intangible assets	10.90
Investment in term deposits with banks	(1,264.56)
Investment in Debt Mutual Funds	(0.01)
Interest received	169.50
<b>Net cash flow (used) in Investing activities (B)</b>	<b>(2,406.36)</b>
<b>C. Cash flow from Financing activities</b>	
Proceeds from issuance of equity share capital	4,000.00
Repayment of borrowings	(1,893.72)
Lease liabilities	(38.16)
Share issue expenses	(146.81)
Interest paid	(161.41)
<b>Net cash flow generated from in financing activities (C)</b>	<b>1,759.90</b>
<b>Net increase in cash and cash equivalents (A+B+C)</b>	<b>637.78</b>
Cash and cash equivalents at the beginning of the Year	246.75
Cash and cash equivalents at the end of the Year	884.53
<b>Cash and cash equivalents comprise:</b>	
<b>Balances with banks</b>	
On current accounts	287.53
Debit balance in bank overdraft	56.10
Fixed deposits with maturity of less than 3 months	537.49
Cash on hand	3.41
<b>Total cash and bank balances at end of the year</b>	<b>884.53</b>

Place: Pune  
Date: 28.05.2022



For and on behalf of Board of Directors  
Krsnaa Diagnostics Limited

*P. Bhatavara*

Pallavi Bhatavara  
Managing Director  
DIN: 03600332

**Krsnaa Diagnostics Limited**

(Formerly known as Krsnaa Diagnostics Private Limited)

CIN:L74900PN2010PLC138068

**Notes to Audited Consolidated Financial Results:**

1. The above consolidated financial results for the quarter and year ended March 31, 2022 have been subjected to statutory audit by the statutory auditors of the group, and reviewed by the audit Committee and approved by the Board of Directors of the Holding Company at the meeting held on May 28, 2022.
2. The above Statement has been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) 2015, as amended.
3. The Holding Company is converted from Private Limited Company to Public Limited Company, pursuant to Special Resolution passed in extraordinary general meeting of the shareholders held on April 25, 2021 and consequently the name of the Company has been changed to Krsnaa Diagnostics Limited pursuant to fresh certificate of Incorporation issued by Registrar of Company dated May 6, 2021.
4. The Holding company has invested into seven special purpose vehicles (SPVs) which are wholly owned subsidiaries namely, - KDPL Diagnostics (Ludhiana) Private Limited on March 22, 2021, KDPL Diagnostics (Amritsar) Private Limited on March 24, 2021, KDPL Diagnostics (Bathinda) Private Limited on March 24, 2021, KDPL Diagnostics (Jalandhar) Private Limited on March 24, 2021, KDPL Diagnostics (Patiala) Private Limited on March 24, 2021, KDPL Diagnostics (SAS Nagar) Private Limited on March 24, 2021 and Krsnaa Diagnostics (Mohali) Private Limited on July 27, 2021.  
  
The company has remitted the amount towards subscription of share capital in these SPVs on April 12, 2021 & August 21, 2021. In the absence of the necessary agreement being executed and transfer of funds for subscription of share capital of these subsidiaries by March 31, 2021, the Holding Company has not consolidated the SPVs in its financial statement for the year ended March 31, 2021.
5. The Holding Company, pursuant to shareholders' resolution dated April 25, 2021, sub-divided its equity share capital by sub-dividing the face value of the equity shares from ₹10 to ₹5 per Equity Share. Accordingly, the issued and paid-up capital of our Company was sub-divided from 6,494,964 equity shares of ₹10 each to 12,989,928 equity shares of ₹5 each.
6. Pursuant to resolution passed at the meeting of Board of Directors held on July 23, 2021, 1,42,01,600 equity shares of Holding Company were issued to compulsory convertible preference shareholders of series A and series C in the ratio 2:1.
7. The Holding Company has completed Initial Public Offer (IPO) of 1,27,31,605 equity shares of the face value of Rs. 5/- each at an issue price of Rs. 954/- per equity share to non employee category shareholders and Rs. 861/- per equity share to employee category shareholders, comprising offer for sale of 85,25,520 equity shares by selling shareholders and fresh issue of 42,06,085 equity shares. The equity shares of the holding company were listed on August 16, 2021 on BSE Limited and National Stock Exchange of India Limited. The total offer expenses have been proportionately allocated between the selling shareholders and the Holding Company as per respective offer size.
8. The Group's operations predominantly relate to providing diagnostic services of radiology and pathology. The Chief Operating Decision Maker (CODM) reviews the operations of the Company as one operating segment. Hence, no separate segment information has been furnished herewith.
9. The management of the Holding Company has made an assessment of the impact of COVID-19 on the Group's operations, financial performance and position as at and for the quarter and year ended March 31, 2022 and has concluded that the impact is primarily on the operational aspects of the business. In making the assessment management has considered the recoverability of trade receivables, investment and other assets and also considered the external and internal information available up to the date of approval of these financial results including status of existing and future customer orders, cash flow projections etc. and concluded that there is no significant impact which is required to be recognized in the financial results. Accordingly, no adjustments have been made to the financial results.
10. The Code on Social Security 2020 ('the Code') relating to employee benefits, during the employment and post-employment, has received Presidential assent on September 28, 2020. The Code has been published in the Gazette of India. Further, the Ministry of Labour and Employment has released draft rules for the Code on November 13, 2020. However, the effective date from which the changes are applicable is yet to be notified and rules for quantifying the financial impact are also not yet issued. The Group will assess the impact of the Code and will give appropriate impact in the financial statements in the period in which the Code becomes effective and the related rules to determine the financial impact are published.
11. The board of directors of the holding company have recommended the dividend of Rs 2.50 per share of the face value of Rs 5 per share for the year ended March 31, 2022. The payment of dividend is subject to approval of shareholders at the ensuing Annual General meeting of the holding company.
12. The numbers for quarter ended March 31, 2022 are the balancing numbers between audited number in respect of full year ended March 31, 2022 and published year to date numbers of nine month ended December 31, 2021.
13. Previous period figures have been regrouped/ rearranged wherever considered necessary.

For and on behalf of Board of Directors  
Krsnaa Diagnostics Limited





Pallavi Bhatevara  
Managing Director

DIN: 03600332

Place: Pune

Date: 28.05.2022

**Independent Auditor's Report on Quarterly Standalone Financial Results and Year to Date Standalone Financial Results pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015**

**To the Board of Directors of Krsnaa Diagnostics Limited**

**Report on the Audit of Standalone Financial Results**

**Opinion**

We have audited the accompanying standalone annual financial results of Krsnaa Diagnostics Limited (hereinafter referred to as 'the Company') for the quarter and year ended March 31, 2022 ('the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Statement:

- (i) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- (ii) give a true and fair view in conformity with the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India, of net profit and other comprehensive income and other financial information of the Company for the year ended March 31, 2022.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.



## **Board of Directors' Responsibilities for the Standalone Financial Results**

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, have been prepared on the basis of the standalone annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of this Statement that give a true and fair view of the net profit and other comprehensive income in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Board of Directors of the Company are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Company, as aforesaid.

In preparing the Statement, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors of the Company are responsible for overseeing the financial reporting process of the Company.

## **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:





- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Company of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



**Other Matters**

The Statement include the results for the quarter ended March 31, 2022 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" which were subject to limited review by us.

Our opinion on the Statement is not modified in respect of the above matter.

**For M S K A & Associates**

Chartered Accountants

ICAI Firm Registration No.105047W

**NITIN  
MANOHAR  
R JUMANI**

Digitally signed by  
NITIN MANOHAR  
JUMANI  
Date: 2022.05.28  
15:59:44 +05'30'



**Nitin Manohar Jumani**

Partner

Membership No. 111700

UDIN: 22111700AJUOWP2091

Place: Pune


Date: May 28, 2022

Statement of Standalone Financial Results for the quarter and year ended March 31, 2022

(INR Million, except earnings per share)

Sr. No.	Particulars	Quarter ended			Year ended	
		March 31, 2022	December 31, 2021	March 31, 2021	March 31, 2022	March 31, 2021
		(Audited)	(Un-audited)	(Audited)	(Audited)	(Audited)
<b>1</b>	<b>Income</b>					
	Revenue from operations	1,078.44	1,063.11	959.12	4,548.90	3,964.56
	Gain on fair value movement of Compulsory Convertible Preference Shares	-	-	-	-	2,527.84
	Other Income	41.21	43.39	28.63	149.28	122.36
	<b>Total Income</b>	<b>1,119.65</b>	<b>1,106.50</b>	<b>987.75</b>	<b>4,698.18</b>	<b>6,614.76</b>
<b>2</b>	<b>Expenses</b>					
	Cost of material consumed	127.03	117.46	152.93	602.96	837.47
	Employee benefits expense	142.67	138.39	62.98	533.32	299.07
	Finance costs	18.31	23.45	65.06	184.89	259.40
	Depreciation and amortization expense	104.45	106.34	97.64	413.87	374.39
	Fees to hospitals and others	248.29	274.39	216.42	1,079.92	1,086.61
	Other expenses	258.31	223.95	194.30	987.22	803.30
	<b>Total Expenses</b>	<b>899.06</b>	<b>883.98</b>	<b>789.33</b>	<b>3,802.18</b>	<b>3,660.24</b>
<b>3</b>	<b>Profit before tax (1) - (2)</b>	<b>220.59</b>	<b>222.52</b>	<b>198.42</b>	<b>896.00</b>	<b>2,954.52</b>
<b>4</b>	<b>Tax expenses</b>					
	Income Tax charge	51.87	44.61	28.09	175.26	76.47
	Deferred tax charge/(credit)	(24.59)	5.60	280.33	13.71	1,028.76
	<b>Total tax expenses</b>	<b>27.28</b>	<b>50.21</b>	<b>308.42</b>	<b>188.97</b>	<b>1,105.23</b>
<b>5</b>	<b>Profit / (loss) for the period/year (3) - (4)</b>	<b>193.31</b>	<b>172.31</b>	<b>(110.00)</b>	<b>707.03</b>	<b>1,849.29</b>
<b>6</b>	<b>Other comprehensive income</b>					
	Items that will not be reclassified subsequently to profit and loss					
	Re-measurement gains / (losses) on defined benefit plans	4.98	(0.10)	(1.49)	4.69	(0.38)
	Income tax effect	(1.25)	0.02	0.42	(1.18)	0.10
	<b>Total other comprehensive Income/(loss) for the period/year</b>	<b>3.73</b>	<b>(0.08)</b>	<b>(1.07)</b>	<b>3.51</b>	<b>(0.28)</b>
<b>7</b>	<b>Total comprehensive income/(loss) for the period/year, net of tax (5+6)</b>	<b>197.04</b>	<b>172.23</b>	<b>(111.07)</b>	<b>710.54</b>	<b>1,849.01</b>
<b>8</b>	<b>Paid-up equity share capital (Face Value of Rs. 10/- each as on March 31, 2021 and Rs. 5/ each as on March 31, 2022 and December 31, 2021)</b>	<b>156.99</b>	<b>156.99</b>	<b>64.95</b>	<b>156.99</b>	<b>64.95</b>
	Instruments entirely equity in nature					2,423.90
	Other equity				6,710.51	(170.20)
	Earnings/(Loss) per share - After Split (Not annualised for quarters)					
	Basic (Rs.)	5.85	5.97	(9.53)	23.66	160.36
	Diluted (Rs.)	5.85	5.95	(9.53)	23.66	12.25

Place: Pune  
Date: 28.05.2022



For and on behalf of Board of Directors  
Krsnaa Diagnostics Limited

*Bhatevara*

Pallavi Bhatevara  
Managing Director  
DIN: 03600332

Krsnaa Diagnostics Limited  
(Formerly known as Krsnaa Diagnostics Private Limited)  
CIN:L74900PN2010PLC138068

Standalone Balance Sheet as at March 31, 2022

(INR Million)

Particulars	As at March 31, 2022 (Audited)	As at March 31, 2021 (Audited)
<b>I. ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	3,833.79	3,072.80
Capital work-in-progress	282.57	37.18
Intangible assets	23.15	12.28
Investments	3.61	2.90
Other financial assets	1,155.15	159.51
Other non-current assets	114.61	279.24
<b>Total non-current assets</b>	<b>5,412.88</b>	<b>3,563.91</b>
<b>Current assets</b>		
Inventories	91.70	72.10
Financial assets		
Trade receivables	593.07	752.89
Cash and cash equivalents	883.24	246.75
Bank balances other than cash and cash equivalent	1,534.28	1,282.37
Other financial assets	121.79	90.08
Other current assets	133.59	84.67
<b>Total current assets</b>	<b>3,357.67</b>	<b>2,528.86</b>
<b>Total Assets</b>	<b>8,770.55</b>	<b>6,092.77</b>
<b>II. EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity share capital	156.99	64.95
Instruments entirely equity in nature		2,423.90
Other equity	6,710.51	(170.20)
<b>Total equity</b>	<b>6,867.50</b>	<b>2,318.65</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
Financial liabilities		
Borrowings	196.22	1,529.26
Lease Liabilities	134.52	150.28
Other financial liabilities	16.39	63.89
Employee benefit obligations	2.61	5.19
Deferred Tax Liabilities	77.94	106.95
Other non-current liabilities	1.25	33.03
<b>Total non-current liabilities</b>	<b>428.93</b>	<b>1,888.60</b>
<b>Current liabilities</b>		
Financial liabilities		
Borrowings	60.08	620.76
Lease Liabilities	19.10	17.49
Trade payables		
i) Total outstanding dues of micro enterprises and small enterprises	3.27	5.37
ii) Total outstanding dues of creditors other than micro enterprise and small enterprise	761.26	827.66
Other financial liabilities	508.16	374.73
Other current liabilities	102.47	30.23
Employee benefit obligations	19.78	9.28
<b>Total Current liabilities</b>	<b>1,474.12</b>	<b>1,885.52</b>
<b>Total Liabilities</b>	<b>1,903.05</b>	<b>3,774.12</b>
<b>Total Equity and Liabilities</b>	<b>8,770.55</b>	<b>6,092.77</b>



For and on behalf of Board of Directors  
Krsnaa Diagnostics Limited

*P. Bhatevara*

Pallavi Bhatevara  
Managing Director  
DIN: 03600332

Place: Pune  
Date: 28.05.2022

Krsnaa Diagnostics Limited  
(Formerly known as Krsnaa Diagnostics Private Limited)  
CIN:L74900PN2010PLC138068

Statement of Standalone Cash Flows for the year ended March 31, 2022

(INR Million)

Particulars	Year Ended	
	March 31, 2022	March 31, 2021
	(Audited)	(Audited)
<b>A. Cash flow from operating activities</b>		
Profit for the period	896.00	2,954.52
Adjustments for:		
Depreciation and amortization expenses	413.87	374.39
Finance cost	184.89	259.40
Interest income	(122.44)	(99.09)
Loss on sale/disposal of assets	2.48	5.06
Provision for credit impaired	8.30	-
Effect of Financial Instruments measured at amortised cost	(7.49)	(7.51)
Gain on fair value movement of Compulsory Convertible Preference Share	-	(2,527.84)
Employee stock option scheme compensation	12.42	8.20
<b>Operating profit before working capital changes</b>	<b>1,388.03</b>	<b>967.13</b>
<b>Changes in working capital</b>		
(Decrease)/increase in trade payables	(68.51)	434.06
(Increase) in inventories	(19.61)	(21.43)
Decrease/(increase) in trade receivables	146.01	(132.59)
Increase in other current liabilities	0.20	6.54
(Decrease) in other non current liabilities	(31.78)	(4.72)
(Decrease) in other non current financial liabilities	(58.00)	(19.48)
Increase in employee payables	12.60	3.67
Increase in other current financial liabilities	11.58	16.36
(Increase)/ decrease in other current financial assets	(75.30)	118.90
Decrease/ (increase) in non current financial assets	35.45	(19.53)
(Increase) in other current assets	(9.27)	(51.73)
Decrease/ (increase) in other non current assets	21.99	(33.85)
<b>Cash generated from operations</b>	<b>1,353.39</b>	<b>1,263.33</b>
Income tax paid	(148.30)	(76.73)
Income tax refund received	82.01	-
<b>Net cash flows generated from operating activities (A)</b>	<b>1,287.10</b>	<b>1,186.60</b>
<b>B. Cash flow from Investing activities</b>		
Payment for property, plant and equipment and intangible assets	(1,322.64)	(710.42)
Proceeds from sale of property, plant and equipment and intangible assets	10.90	20.00
Investment in term deposits with banks (having original maturity of more than three months)	(1,264.56)	(56.97)
Investment in Debt Mutual Fund	(0.01)	-
Loan given to subsidiaries	(3.48)	-
Investment in Equity Instruments of subsidiaries	(0.70)	-
Interest received	169.51	73.69
<b>Net cash flow used in investing activities (B)</b>	<b>(2,410.98)</b>	<b>(673.70)</b>
<b>C. Cash flow from Financing activities</b>		
Proceeds from issuance of equity share capital	4,000.00	7.32
Proceeds/(repayment) of borrowings (net)	(1,893.72)	461.49
Increase/(decrease) in Lease liabilities	(37.66)	(34.90)
Share issue expenses	(146.85)	-
Interest paid	(161.40)	(233.61)
<b>Net cash flow generated from in financing activities (C)</b>	<b>1,760.37</b>	<b>200.30</b>
<b>Net increase in cash and cash equivalents (A+B+C)</b>	<b>636.49</b>	<b>713.20</b>
<b>Cash and cash equivalents at the beginning of the year</b>	<b>246.75</b>	<b>(466.45)</b>
<b>Cash and cash equivalents at the end of the year</b>	<b>883.24</b>	<b>246.75</b>
<b>Cash and cash equivalents comprise:</b>		
<b>Balances with banks</b>		
On current accounts	286.56	237.98
Debit balance in bank overdraft	56.09	3.12
Fixed deposits with maturity of less than 3 months	537.49	0.00
<b>Cash on hand</b>	3.10	5.65
<b>Total cash and bank balances at end of the year</b>	<b>883.24</b>	<b>246.75</b>

Place: Pune  
Date: 28.05.2022



For and on behalf of Board Directors  
Krsnaa Diagnostics Limited

*P. Bhatevora*  
Pallavi Bhatevora  
Managing Director  
DIN: 03600332

**Krsnaa Diagnostics Limited**

(Formerly known as Krsnaa Diagnostics Private Limited)

CIN:L74900PN2010PLC138068

**Notes to Audited Standalone Financial Results:**

1. The above standalone financial results for the quarter and year ended March 31, 2022 have been subjected to statutory audit by the statutory auditors of the Company and reviewed by the Audit Committee and approved by the Board of Directors of the Company at the meeting held on May 28, 2022.
2. The above Statement has been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) 2015, as amended.
3. The Company is converted from Private Limited Company to Public Limited Company, pursuant to Special Resolution passed in extraordinary general meeting of the shareholders held on April 25, 2021 and consequently the name of the Company has been changed to Krsnaa Diagnostics Limited pursuant to fresh Certificate of Incorporation issued by Registrar of Company dated May 6, 2021.
4. The Company, pursuant to shareholders' resolution dated April 25, 2021, sub-divided its equity share capital by sub-dividing the face value of the Equity Shares from ₹10 to ₹5 per Equity Share. Accordingly, the issued and paid-up capital of our Company was sub-divided from 6,494,964 Equity Shares of ₹10 each to 12,989,928 Equity Shares of ₹5 each.
5. Pursuant to resolution passed at the meeting of Board of Directors held on July 23, 2021, 1,42,01,600 equity shares were issued to compulsory convertible preference shareholders of series A and series C in the ratio 2:1.
6. The Company has completed Initial Public Offer (IPO) of 1,27,31,605 Equity Shares of the face value of Rs. 5/- each at an issue price of Rs. 954/- per Equity Share to non employee category shareholders and Rs. 861/- per Equity Share to employee category shareholders, comprising offer for sale of 85,25,520 equity shares by selling shareholders and fresh issue of 42,06,085 equity shares. The Equity Shares of the Company were listed on August 16, 2021 on BSE Limited and National Stock Exchange of India Limited. The total offer expenses have been proportionately allocated between the selling shareholders and the Company as per respective offer size.
7. The company has invested into seven special purpose vehicles (SPVs) which are wholly owned subsidiaries namely, - KDPL Diagnostics (Ludhiana) Private Limited on March 22, 2021, KDPL Diagnostics (Amritsar) Private Limited on March 24, 2021, KDPL Diagnostics (Bathinda) Private Limited on March 24, 2021, KDPL Diagnostics (Jalandhar) Private Limited on March 24, 2021, KDPL Diagnostics (Patiala) Private Limited on March 24, 2021, KDPL Diagnostics (SAS Nagar) Private Limited on March 24, 2021 and Krsnaa Diagnostics (Mohali) Private Limited on July 27, 2021. The company has remitted the amount towards subscription of share capital in these SPVs on April 12, 2021 and August 21, 2021.
8. The Company's operations predominantly relate to providing diagnostic services in radiology and pathology services. The Chief Operating Decision Maker (CODM) reviews the operations of the Company as one operating segment. Hence, no separate segment information has been furnished herewith.
9. The management has made an assessment of the impact of COVID-19 on the Company's operations, financial performance and position as at and for the quarter and year ended March 31, 2022 and has concluded that the impact is primarily on the operational aspects of the business. In making the assessment, management has considered the recoverability of trade receivables, investment and other assets and also considered the external and internal information available up to the date of approval of these financial results including status of existing and future customer orders, cash flow projections etc. and concluded that there is no significant impact which is required to be recognized in the financial results. Accordingly, no adjustments have been made to the financial results.
10. The Code on Social Security 2020 ('the Code') relating to employee benefits, during the employment and post-employment, has received Presidential assent on September 28, 2020. The Code has been published in the Gazette of India. Further, the Ministry of Labour and Employment has released draft rules for the Code on November 13, 2020. However, the effective date from which the changes are applicable is yet to be notified and rules for quantifying the financial impact are also not yet issued. The Company will assess the impact of the Code and will give appropriate impact in the financial statements in the period in which the Code becomes effective and the related rules to determine the financial impact are published.
11. The board of directors have recommended the dividend of Rs. 2.50 per share of the face value of Rs 5 per share for the year ended March 31, 2022. The payment of dividend is subject to approval of shareholders at the ensuing Annual General meeting of the company.
12. The numbers for quarter ended March 31, 2022 and March 31, 2021 are the balancing numbers between audited number in respect of full year ended March 31, 2022 and published year to date numbers of nine month ended December 31, 2021, and audited numbers of full year ended March 31, 2021 and special purpose audit for nine month ended December 31, 2020 respectively.
13. Previous period figures have been regrouped/ rearranged wherever considered necessary.

For and on behalf of Board of Directors  
Krsnaa Diagnostics Limited



  
Pallavi Bhatevara  
Managing Director  
DIN: 03600332

Place: Pune  
Date: 28.05.2022

Date: 28<sup>th</sup> May, 2022

BSE Ltd.  
Corporate Service Department  
1<sup>st</sup> Floor, P.J. Towers,  
Dalal Street,  
Mumbai 400 001

The National Stock Exchange of India Ltd.  
Exchange Plaza, 3<sup>rd</sup> Floor,  
Plot No. C/1, 'G' Block,  
Bandra Kurla Complex, Bandra (E),  
Mumbai 400 051

Scrip ID: KRSNAA  
Scrip Code: 543328

Symbol: KRSNAA  
Series: EQ

Dear Sir/Madam,

Subject: Declaration pursuant to Regulation 33(3)(d) of the Securities and Exchange Board of India  
(Listing Obligations and Disclosure Requirements) Regulations, 2015 [the SEBI (LODR)  
Regulations].

We, Pallavi Bhatevara, Managing Director and Pawan Daga, Chief Financial Officer of Krsnaa Diagnostics Limited, having its Registered Office at S. No. 243/A, Hissa No 6, CTS No. 4519, 4519/1, Near Chinchwad Station, Chinchwad, Pune - 411019, India, hereby declare that, the Statutory Auditors of the Company, MSKA & Associates (FRN: 105047W) have issued an Audit Report with unmodified opinion on the Audited Financial Results of the Company (Consolidated & Standalone) for the quarter and year ended March 31, 2022.

This declaration is given in compliance to Regulation 33(3)(d) of the SEBI (LODR) Regulations, 2015, as amended by the SEBI (LODR) (Amendment) Regulations, 2016, vide Notification No. SEBI/LAD-NRO/GN/2016-17/001, dated May 25, 2016 and Circular No. CIR/CFD/CMD/56/2016, dated May 27, 2016.

Kindly take this declaration on record.

Thanking You.

For Krsnaa Diagnostics Limited



Pallavi Bhatevara  
Managing Director





Pawan Daga  
Chief Financial Officer